Iovance Biotherapeutics received conditional approval for its drug lifileucel, expanding its potential market reach.
2 reports, 2 independent
Updated Aug 30
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Iovance Biotherapeutics received conditional approval for its drug lifileucel, expanding its potential market reach.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Iovance Biotherapeutics
American biopharmaceutical startup
Nothing else this week.
-
lifileucel
experimental autologous cell therapy for metastatic melanoma
Nothing else this week.
Related events
Coverage
Newest first; wire copies grouped- Simply Wall St.Iovance Biotherapeutics (IOVA) Raises US$350 Million in Equity Offering Iovance Biotherapeutics saw its share price increase by 27% last quarter, coinciding with several key developments. Health Cana
- Motley FoolIf You'd Invested $1,000 in IOVA 3 Years Ago, Here's How Much You'd Have Today The shares trade well below their all-time high. The company's leading drug isn't yet as successful as many hoped. 10 st